Please assess the completion status of the following clinical trial:

Trial Title: Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for Liver Recipients:~* Received liver from living parent donor~* Received transplant at least 4 years prior to study entry~* Less than 18 years of age at time of transplant~* Parent or guardian willing to provide informed consent~Inclusion Criteria for Liver Donors:~* Willing to participate in this study~Exclusion Criteria for Liver Recipients:~* Underwent transplant because of liver failure related to autoimmune disease~* Underwent transplant of a second organ simultaneously with or after liver transplant OR liver retransplantation~* Receiving immunosuppression with more than one drug~* 50% increase in dose of current immunosuppressive drug~* HIV infection~* Hepatitis B or C virus infection~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Immunosuppression Withdrawal (Type: EXPERIMENTAL): Recipients of parental living donor liver transplants 4 or more years prior to trial enrollment, who also had stable allograft function during the preceding 6 months while taking a single immunosuppressive drug were permitted to undergo withdrawal of immunosuppression therapy. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.~Participants are carefully evaluated/monitored throughout the study by assessments including but not limited to liver biopsy, liver tests and clinic visits, alloantibodies, autoantibodies and quantitative immunoglobulin G test results.

Based on this trial design, predict the completion outcome and termination type (if applicable).